US grant · National Institutes of Health
Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
See official listing Closes November 19, 2026
Official listing and how to apply Full funding notice
Source: Grants.gov · Last checked
Key facts
| Funder | National Institutes of Health |
|---|---|
| Part of | Department of Health and Human Services |
| Opportunity number | PAR-25-226 |
| Amount per award | See official listing |
| Opens | November 22, 2024 |
| Closes | November 19, 2026 (9 days left) |
| Who can apply | Schools and universities, Businesses, Government, Nonprofits, Other (see listing), Tribal organizations |
| Applicant types listed | Independent school districts; Native American tribal organizations (other than Federally recognized tribal governments); Native American tribal governments (Federally recognized); For profit organizations other than small businesses; Small businesses; Public housing authorities/Indian housing authorities; Special district governments; Others (see text field entitled "Additional Information on Eligibility" for clarification); City or township governments; State governments; Private institutions of higher education; Public and State controlled institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; County governments; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education |
| State or area | Nationwide |
| Cost sharing or match | Not required |
| Status | Open |
| Source | Grants.gov |
| Last checked | November 10, 2026 |
About this grant
Summary from the official listing on Grants.gov:
The purpose of this Notice of Funding Opportunity (NOFO) is to invite applications that bundle independent protocols for phase 1 clinical trials with phase 1b/phase 2a clinical trials to streamline the early-stage evaluation of promising pharmacological interventions for Alzheimer's disease (AD) and Alzheimer's disease-related Dementias (ADRD). Candidate interventions evaluated through this program, which can include small molecules or biologics for example, must engage non-amyloid/non-tau mechanisms and aim to address cognitive and/or neuropsychiatric symptoms in individuals across the spectrum from pre-symptomatic to more severe stages of disease. This NOFO uses the UG3/UH3 phased award mechanism and proposals must include prespecified, go/no-go safety and tolerability milestones that gate the advance from phase 1 to latter stages of clinical development.
Eligibility
Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Details are copied from the official source and can change. Check the official listing before you apply. Grant Writing Company is not affiliated with this funder.
Want an expert to write it with you?
Grant Writing Company researches funders, writes organization proposals to each funder's instructions, and checks the package before you submit. experience since 2006. Funders decide every award.